Perlegen Pulls IPO

Perlegen Sciences Inc., a Mountain View, Calif.-based developer of genetically-targeted medicines, has withdrawn registration of a proposed $115 million IPO. It had originally filed last April, with Lehman Brothers and Deutsche Bank Securities serving as co-lead underwriters. The company said that its withdrawal was “consistent with the public interest and the protection of investors.” Perlegen has raised around $256 million in total VC funding since its 2000 inception, from firms like Affymetrix, Pfizer, Maverick Capital, MPM Capital and CMEA Ventures.